pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,652 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1782Endpoints1388Fierce Biotech706BioSpace698BioPharma Dive524raps234onclive165fda recalls113
therapy area
allOncology12306Rare Disease3217Immunology2862Cardiology2744Hematology2177Pulmonology2138Vaccines
  • Health AI progress limited by bad data, newsletter notes
    The latest AI Prognosis newsletter highlights that the quality of health data is a major obstacle for building useful AI tools in medicine. The author explains that many existing datasets contain…
    STAT · 6mo agoNeutral↗ source
  • HHS focuses on overmedication as cruise ship hantavirus outbreak prompts port change
    The Health and Human Services department announced new efforts to curb excessive prescribing, highlighting concerns about overmedication in the United States. At the same time, a cruise ship ancho…
    STAT · 6mo agoNeutral↗ source
← prev
page 102 of 107
next →
fda medwatch111
globenewswire health73
fda press59
1794
Psychiatry & CNS1204
Ophthalmology1060
Pain777
Endocrinology & Metabolism776
Nephrology760
OpenAI’s health AI policy blueprint seen as reasonable yet self‑serving, experts say
OpenAI has expanded its health‑focused AI tools, rolling out ChatGPT Health for consumers, a hospital‑oriented ChatGPT for Healthcare, and a version for clinicians. Alongside the clinician chatbot,…
STAT · 6mo agoRegulatoryNegative↗ source
  • PeaceHealth abandons plan to outsource Oregon emergency doctors to ApolloMD after lawsuit and local opposition
    PeaceHealth, a nonprofit health system in Oregon, announced Wednesday that it will not move its emergency department staffing to the national physician staffing firm ApolloMD. The decision reverse…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Dementia care faces ambiguous loss, a unique grief that strains relationships
    Jason Karlawish, a professor of medicine and neurology at the University of Pennsylvania, wrote an opinion piece on the concept of ambiguous loss in dementia care. He reflects on a recent interview…
    STAT · 6mo agoNeutral↗ source
  • Dr. Glaucomflecken protests corporate staffing of PeaceHealth emergency department in Oregon
    Dr. Glaucomflecken, the online persona of physician Will Flanary, hosts the First Opinion Podcast where he blends humor with health‑care commentary. He has become a vocal critic of PeaceHealth’s p…
    STAT · 6mo agoNegative↗ source
  • Cytokinetics’ Myqorzo hits twin efficacy targets in genetic heart disease trial, while Viridian reports positive Phase 3 data for elegrobart
    Cytokinetics announced that its experimental heart‑failure drug Myqorzo achieved both primary efficacy endpoints in a study of patients with genetic cardiomyopathy, showing significant symptom impr…
    STAT · 6mo agoPositive readoutPositive↗ source
  • Cytokinetics' Myqorzo hits both primary endpoints in Phase 3 trial for non-obstructive hypertrophic cardiomyopathy
    Cytokinetics announced that its drug Myqorzo achieved the dual efficacy targets in the Phase 3 ACACIA trial, which evaluated patients with non-obstructive hypertrophic cardiomyopathy (HCM), an inhe…
    STAT · 6mo agoPositive readoutPositive↗ source
  • Hantavirus outbreak on cruise ship highlights risks of U.S. exclusion from WHO
    Three passengers have died and seven others are ill after a suspected hantavirus infection was identified on a cruise vessel anchored off Cape Verde. The World Health Organization has taken the lea…
    STAT · 6mo agoRegulatoryNegative↗ source
  • J&J's IBD combo therapy misses statistical goal but will be tested in a focused patient subgroup
    Johnson & Johnson reported that its experimental combination of Tremfya and Simponi, called JNJ-4804, did not achieve a statistically significant improvement in a Phase 2b study of inflammatory bow…
    STAT · 6mo agoNegative readoutNegative↗ source
  • Pharma's reputation among patient groups edges up to 57% but access and pricing concerns linger
    Patient groups surveyed by research firm PatientView gave drugmakers a 57% “good” or “excellent” reputation rating, the highest level since 2023. The survey covered more than 2,400 groups in 35 cou…
    STAT · 6mo agoNeutral↗ source
  • GOP Oversight Chair James Comer Targets AMA Billing Codes Over Fraud Concerns
    House Oversight Committee Chair James Comer, a Republican from Kentucky, is directing new scrutiny toward the American Medical Association's Current Procedural Terminology (CPT) billing codes, alle…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • STAT+ examines AI diagnostic claims, telehealth abortion access and Epic lawsuit in latest health tech newsletter
    STAT+ published a health‑tech newsletter that asks whether artificial intelligence has truly outperformed physicians in diagnosing disease, citing a high‑profile study on AI diagnostic performance.…
    STAT · 6mo agoNeutral↗ source
  • RFK Jr. proposes steps to curb SSRI prescriptions; J&J pushes IBD drug; French regulators fine Novo, Lilly over weight-loss ads
    U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a set of initiatives aimed at reducing the prescribing of selective serotonin reuptake inhibitors, the most widely used clas…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • STAT+: Top lawmaker takes aim at doctor lobby, linking AMA’s billing codes to fraud fight
    A top Republican is asking if the AMA's codes are helping to fuel health care fraud.
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Supreme Court temporarily restores broad access to abortion pill mifepristone
    The Supreme Court issued an order on Monday that temporarily reinstates wide availability of the abortion medication mifepristone. The order follows a federal appeals court decision that had threat…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Returning doctors face unexpected hurdles and new chances to improve care in their home countries
    The opinion piece argues that the common "brain drain" story about health workers leaving low‑income nations overlooks what happens when they come back. The author cites a breast surgeon who train…
    STAT · 6mo agoNeutral↗ source
  • China's new supply chain rules threaten Western pharma as Beijing tightens control over biotech imports
    China has rapidly expanded its role in drug development, moving from less than 8% of global clinical trials in 2010 to overtaking the United States in trial volume by 2020, with more than 5,000 tri…
    STAT · 6mo agoRegulatoryNegative↗ source
  • French regulator fines Novo Nordisk and Eli Lilly for misleading weight loss ads
    French medicines regulator ANSM imposed fines on Novo Nordisk and Eli Lilly for advertising practices linked to their weight loss drugs. Novo Nordisk was fined about $2 million for ads promoting W…
    STAT · 6mo agoRegulatoryNegative↗ source
  • 5th Circuit reinstates in-person dispensing for mifepristone, prompting Supreme Court stay and industry concerns
    The 5th Circuit Court of Appeals reversed a prior ruling and required mifepristone to be dispensed only in person. Danco, the drug's maker, asked the Supreme Court for relief and received a one-wee…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Supreme Court blocks restriction, keeps mifepristone available via telehealth, mail and pharmacies
    The Supreme Court issued an order on Monday that temporarily restores broad access to the abortion medication mifepristone, overturning a recent appellate court ruling that would have limited its d…
    STAT · 6mo agoRegulatoryPositive↗ source
  • UCB to buy antibody maker targeting autoimmune diseases
    UCB announced it will acquire a company that develops antibody treatments for autoimmune disorders. The deal expands UCB’s pipeline in a therapeutic area where it seeks to strengthen its market pos…
    STAT · 6mo agoDealNeutral↗ source
  • Two drugmakers petition Supreme Court to reinstate mail-order access to abortion pill mifepristone
    Two drugmakers, Danco Laboratories and GenBioPro, have asked the U.S. Supreme Court to restore mail-order distribution of mifepristone, the abortion pill. The request follows a recent appellate co…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Federal appeals court rules mifepristone can only be dispensed in person, blocking mail distribution
    A federal appeals court issued a ruling that mifepristone, the medication used for medical abortions, must be provided only in person at clinics. The decision overturns the FDA regulation that had…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Latus Bio secures $42 million to launch Huntington’s disease gene therapy trial
    Biotech startup Latus Bio announced it has raised $42 million to fund its first clinical trials, including a gene‑therapy program aimed at Huntington’s disease. The capital will be used to seek FDA…
    STAT · 6mo agoDealPositive↗ source